浜у搧涓績
鑱旂郴鎴戜滑
閿€鍞笓鐢細
鍦板潃锛氬寳浜競娴锋穩鍖鸿タ灏忓彛璺?6鍙蜂腑鍏虫潙涓滃崌绉戞妧鍥瑿-1妤间笁灞侟/p>

- 浜у搧鎻忚堪
- 鍙傝€冩枃鐚
-
銆€銆€Y鍨嬭仛涔欎簩閱嘚HS閰槸鑷富鐮斿彂鐨刌鍨嬬粨鏋勶紝鍏锋湁2涓狿EG閾惧拰涓€涓椿鎬ч叝鍩哄洜锛屽彲浠ョ敤鏉ョ敓浜ц泲鐧芥垨鍏朵粬鐢熺墿鍒嗗瓙涓殑璧栨皑閰镐笂鐨勬皑鍩鸿繘琛屽弽搴斻€俌-NHS鍙互鍦≒H=7-8鐨勭紦鍐叉恫涓湪杈冪煭鐨勬椂闂村唴涓嶯H2杩涜鑱氫箼浜岄唶鍖栥€傜敱浜嶻-NHS鍏锋湁鐙壒鐨勭┖闂寸粨鏋勪娇瀹冩洿鍏锋湁閫夋嫨鎬с€侟/p>
銆€銆€閿嚡绉戞妧鎻愪緵鍒嗚鏈嶅姟锛岄渶瑕佹敹鍙栧垎瑁呰垂鐢紝濡傛灉鎮ㄩ渶瑕佸垎瑁呬负鍏朵粬瑙勬牸璇蜂笌鎴戜滑鑱旂郴銆侟/p>
銆€銆€閿嚡绉戞妧鍚屾椂鎻愪緵鍏朵粬鍒嗗瓙閲忕殑Y鍨嬭鐢熺墿浜у搧锛屽浣犻渶瑕佽涓庢垜鍙竤ales@jenkem.com鑱旂郴銆侟/p>
銆€銆€閿嚡绉戞妧鎻愪緵澶ф壒閲忕敓浜т骇鍝佸強GMP绾у埆浜у搧锛屽闇€鎶ヤ环璇蜂笌鎴戜滑鑱旂郴銆侟/p>
-
銆€銆€References:
銆€銆€1. AlQahtani, A.D., et al., Production of “biobetter” glucarpidase variants to improve drug detoxification and antibody directed enzyme prodrug therapy for cancer treatment, European Journal of Pharmaceutical Sciences, 2019, 127, P. 79-91.
銆€銆€2. Haruta, K., et al., A Novel PEGylation Method for Improving the Pharmacokinetic Properties of Anti-Interleukin-17A RNA Aptamers, Nucleic acid therapeutics, 2017, 27(1):36-44.
銆€銆€3. Guo, L., et al., Application Instructions for Y-NHS-40K for Amine PEGylation, click link.
銆€銆€4. Masao, H., et al., Chemically Modified Interleukin-6 Aptamer Inhibits Development of Collagen-Induced Arthritis in Cynomolgus Monkeys, Nucleic Acid Therapeutics, 2015.
銆€銆€5. Winship, A.L., Interleukin-11 alters placentation and causes preeclampsia features in mice, Proc Natl Acad Sci U S A., 2015, 112(52):15928-33.
銆€銆€6. Risitano, A.M., et al., Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria, Blood Mar, 2014, 123 (13) 2094-2101.
銆€銆€7. Roccaro, Aldo M. et al., SDF-1 Inhibition Targets the Bone Marrow Niche for Cancer Therapy, Cell Reports, 2014, 9 (1), p: 118 – 128.
銆€銆€8. Stefan, N., et al., Novel Prodrug-Like Fusion Toxin with Protease-Sensitive Bioorthogonal PEGylation for Tumor Targeting, Bioconjugate chemistry, 2014, 25.12: 2144-2156.
銆€銆€9. Ashokan, A., et al., Multifunctional calcium phosphate nano-contrast agent for combined nuclear, magnetic and near-infrared in vivo imaging. Biomaterials, 2013, 34(29): p. 7143-7157.
銆€銆€10. Khan, M.A., et al., Targeting complement component 5a promotes vascular integrity and limits airway remodeling, PNAS, 2013, 110(15) p:6061-6066.
銆€銆€11. Dai, C.Y., et al., Preparation and evaluation of a new releasable PEGylated tumor necrosis factor-α (TNF-α) conjugate for therapeutic application, Science China Life Sciences, 2013, 56.1 : 51-58.
銆€銆€12. Dai, C.Y., et al., Linkage with cathepsin B-sensitive dipeptide promotes the in vitro and in vivo anticancer activity of PEGylated tumor necrosis factor-alpha (TNF-α) against murine fibrosarcoma, Science China Life Sci, 2011, 54(2): 128–138.
銆€銆€13. Menkhorst, E., et al., Vaginally Administered PEGylated LIF Antagonist Blocked Embryo Implantation and Eliminated NonTarget Effects on Bone in Mice, PLoS ONE, 2011, 6 (5) e19665.
銆€銆€14. Cai, Y., et al., Separation of exenatide analogue mono-PEGylated with 40 kDA polyethylene glycol by cation exchange chromatography, Journal of Chromatography A, 2011, 1218:39, P. 6953-6960.
銆€銆€15. Wang, Y-J., et al., PEGylation markedly enhances the in vivo potency of recombinant human non-glycosylated erythropoietin: A comparison with glycosylated erythropoietin, Journal of Controlled Release, 2010, 145:3, p. 306-313.
銆€銆€16. Marcus, Y., et al., Turning Low-Molecular-Weight Drugs into Prolonged Acting Prodrugs by Reversible Pegylation: A Study with Gentamicin, Journal of Medicinal Chemistry, 2008, 51 (14), 4300-4305.
銆€銆€17. Wang, S., et al., Y-type polyethylene glycol modified G-CSF and preparation method and use thereof. Patent CN200780051378, 2007.
銆€銆€18. Zhou, W., et al., Interferon alpha 2a modified by polyethylene glycol, its synthesis process and application. Patent CN200780050541, 2007.
銆€銆€19. Zhou, W., et al., Interferon alpha 2b modified by polyethylene glycol, its synthesis process and application. Patent CN200780050542, 2007.
銆€銆€20. Zhou, W., et al., Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof. Patent CN200880009718, 2008.
浜у搧璇环